ArticleProceedings of the National Academy of Sciences of the United States of America2026
Switching of the c-Myc protein degradation pathway depending on the PP2A-B55α complex levels.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Switching of the c-Myc protein degradation pathway depending on the PP2A-B55α complex levels.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
The transcription factor c-Myc is a master oncoprotein that regulates over 15% of all genes. Protein phosphatase 2A (PP2A), a crucial tumor suppressor, destabilizes c-Myc protein. Classically, PP2A-mediated dephosphorylation of Ser62 followed by Thr58 phosphorylation was thought to promote ubiquitination of c-Myc by the E3 ligase F-box and WD repeat domain containing 7 (FBXW7). However, recent evidence indicates that FBXW7 preferentially recognizes c-Myc when both Thr58 and Ser62 are phosphorylated, leaving the mechanism underlying PP2A-induced c-Myc degradation unsolved. Here, we demonstrate that the PP2A-B55α complex, which directly dephosphorylates c-Myc at Thr58, regulates two distinct degradation pathways in a biphasic manner: B55α suppression increases Thr58 phosphorylation and enhances FBXW7-dependent degradation, whereas B55α overexpression promotes Thr58-independent, ubiquitin-protein ligase E3 component N-recognin 5 (UBR5)-mediated degradation. We further show that the PP2A-B55α complex binds and dephosphorylates UBR5. In contrast, B55δ, which belongs to the same B55 family and shares a common core structure, exhibits weaker UBR5 binding affinity and fails to induce c-Myc degradation. Our findings identify PP2A-B55α as a context-dependent molecular switch for c-Myc degradation and provide a unified framework that resolves the paradox linking PP2A activation to c-Myc destabilization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.